chronic kidney disease a team based quality improvement
play

Chronic Kidney Disease A Team-Based Quality Improvement Project Implementing The EMR Participants Attending Physician: John Malaty, MD Resident Physician Investi gators : John George, MD David Kramer, DO Dale Taylor, MD

0 downloads 3 Views 4,75 MB Size Report
  1. Chronic Kidney Disease A Team-Based Quality Improvement Project Implementing The EMR

  2. Participants • Attending Physician: John Malaty, MD • Resident Physician Investi gators : – John George, MD – David Kramer, DO – Dale Taylor, MD • Study Coordinators: – Paulette Blanc, MPH – Alyson Listhaus, MPH

  3. Other Participants – Sapna Amin, MD – Sally Hinman, MD – Loumarie Colon, MD – Kim Lynch, MSHI – Jeffrey Costain, MD – Jessica Prince, MD – Anjalee Dave, MD – Keiran Shute, MD – George Eldayrie, MD – Jacob Szereszewski, MD And of course all of our wonderful nursing and front office staff!

  4. Disclosures • None

  5. Learning Objectives After attending this session, you will be able to: • Perform a practical, team-based QI project in your own residency program or practice • More effectively utilize technology to automate processes to efficiently manage chronic diseases by improving adherence to guidelines • Discuss the national guidelines for chronic kidney disease (CKD) management

  6. Why QI? Why EMR? Why Team-Based? • It is important to: – use quality markers and national guidelines to improve patient care – integrate technology into practice and utilize your EMR to improve patient care – work as a team to evaluate and manage patients – manage an efficient and effective healthcare team

  7. Why CKD? • Stage 3 or 4 CKD affects 8.05% of the US population, as measured from 1999-2004 • Patients with CKD have increased morbidity and a two-fold risk of all-cause mortality • Patients with CKD have decreased quality of life and increased cost of care • Patients don’t complain of CKD during visits

  8. Roles of the Healthcare Team  Researched CKD national guidelines and recommendations Residents  Kidney Disease Outcomes Quality Initiative (KDOQI), Joint National and Faculty Committee (JNC8), American College of Physicians (ACP)  Created an EMR template addressing pertinent aspects Improved Epic IT Staff of care with the ability to reproduce data from smartlists  Generated daily reports of clinic patients to Patient Care! Front identify those with depressed eGFRs Office Staff  Flagged encounter forms of Nursing those with depressed eGFRs Staff  Used the template Residents and collected data and Faculty

  9. QI Aims • Primary Aim: – Achieve BP < 140/90 in Stage III-IV CKD patients • Secondary Aims: – Identify and stage patients with CKD – Optimize DM management – Reduce ASCVD risk with statin therapy – Improve renal protection with ACE-I/ARB therapy – Vaccinate against influenza

  10. Our EPIC Template .CKD CKD definition: abnormalities of kidney structure or function present for >3 months with health implications or eGFR < 60 mL/min/1.73m 2 for >3 months.

  11. Our EPIC Template

  12. Our EPIC Template GFR Category / Stage of CKD eGFR ≥ 90 Stage I ≥ 60 Stage II ≥ 30 Stage III ≥ 15 Stage IV Stage V < 15

  13. Our EPIC Template JNC8 Recommendation: target blood pressure for patients with CKD is < 140/90 mmHg for all ages KDOQI Recommendation: target blood pressure for patients with CKD without albuminuria is ≤ 140/90 mmHg and for patients with CKD and albumin excretion ≥ 30mg/24hr is ≤ 130/80 mmHg

  14. Our EPIC Template KDOQI Recommendation: target HbA1c for patients with CKD is ~7% to prevent or delay microvascular complications of diabetes mellitus (higher target acceptable for those with limited life expectancy, comorbid conditions, or risk of hypoglycemia)

  15. Our EPIC Template KDOQI Recommendation: statin therapy is recommended for patients with CKD who are not treated with dialysis in the setting of DM, CAD, TIA/CVA, ASCVD 10- year risk >7.5%, or age ≥ 50

  16. Our EPIC Template KDOQI Recommendation: ACE-I/ARB therapy is recommended for patients with CKD who have urine albumin excretion > 300mg/24 hrs or have diabetes mellitus ACP Recommendation: screening for proteinuria should not be performed in those already on ACE-I/ARB therapy

  17. Our EPIC Template KDOQI Recommendation: influenza vaccination is recommended for all patients with CKD unless otherwise contraindicated

  18. QI Review • Primary Aim was met: – Improvement of BP in CKD patients was noted • Secondary Aims: – More patients with CKD have been identified – More patients on statin therapy to reduce ASCVD risk – More patients needing ACE-I/ARB therapy identified – DM control has not improved but those needing HbA1c measurement are better identified – Flu vaccine rates have not improved but those needing vaccination are better identified

  19.  Primar ary Aim: BP < < 140/ 140/90 2015 2014 D 16, 21% A 11, 48% 12, 52% 62, 79% T P-value = 0.001 A 2014 2015 At Goal (BP < 140/90) At Goal (BP < 140/90) Not at Goal (BP ≥ 140/90) Not at Goal (BP ≥ 140/90)

  20.  Identification of C CKD 2015 D 20, 26% CKD on Problem List CKD NOT on Problem List A 58, 74% T Stage of CKD 70 60 II A 50 III 40 30 IV 20 V 10 0 2014 2015

  21.  Statin T Therapy 2014 2015 6, 8% D 5, 22% A 18, 78% 72, 92% T P-value = 0.000 KDOQI guidelines for statin therapy changed and simplified after 2013-2014 data collection. 2014 2015 Evaluated Lipids? Statin Therapy? A Already On Statin Yes, On Statin LDL <100, TG <150 No, Added Statin LDL >100, Add Statin No, Statin Refused Statin LDL >100, TG >150 No, Contraindication No Lipid Panel No, Address Statin Later

  22.  AC ACE-I/AR ARB Therapy 1, 4% 2014 2015 D 10, 13% 4, 18% 14, 18% A 40, 51% 18, 78% 3, 4% 11, 14% T 2014 2015 On ACE/ARB? Microalbuminuria? A On ACE-I/ARB On ACE-I/ARB ACE-I/ARB Added Alb:Cr < 30, Did not check Contraindicated Alb:Cr > 30, Not on therapy Alb:Cr to be ordered in future, Not on therapy Alb:Cr ordered, Not on therapy

  23.  ACE-I/AR AC ARB Therapy 2015 D 1, 6% A T 15, 94% A On ACE-I/ARB Not on therapy

  24. X Diabetes C Contr trol 2014 2015 1, 4% D 19, 24% A 59, 76% 22, 96% T P-value = 1.996113 A 2014 2015 HbA1c < 7 HbA1c < 7 HbA1C ≥ 7 - Addressed HbA1C ≥ 7 - Addressed HbA1C ≥ 7 -Higher Goal HbA1C ≥ 7 -Higher Goal HbA1c not checked HbA1c not checked

  25. X Infl fluenza Vacci ccinati tion 2014 2015 1, 4% D 21, 27% A 57, 73% 22, 96% T P-value = 1.997585 A 2014 2015 Flu Vaccine Received Flu Vaccine Received Flu Vaccine Refused Flu Vaccine Refused Flu Vaccine Contraindicated Flu Vaccine Contraindicated Address Flu Vaccine Later Address Flu Vaccine Later

  26. References National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: • Evaluation, Classification and Stratification. Am J Kidney Dis 39:S1-S266,2002 (suppl 1). Including all Updates and Commentaries published by The National Kidney Foundation Kidney Disease – Outcomes Quality Initiative (NKF KDOQI) which can be found at: https://www.kidney.org/professionals/guidelines/guidelines_commentaries – James PA, Oparil S, Carter B, et al. 2014 Evidence-Based Guideline for the Management of High • Blood Pressure in Adults (JNC8). JAMA. 2014;311(5):507-520. doi:10.1001/jama.2013.284427. Qaseem A, Hopkins RH, Sweet, DE, et al. Screening, Monitoring, and Treatment of Stage 1 to 3 • Chronic Kidney Disease: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2013;159(12):835-847. doi:10.7326/0003-4819-159-12-201312170-00726 Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. • JAMA. 2007;298(17):2038-47. Selvin E, Manzi J, Stevens LA, et al. Calibration of serum creatinine in the National Health and • Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis. 2007;50(6):918-26.

  27. Questions / Discussions

Recommend Documents


dizzines zziness chronic kidney disease worldwide
dizzines zziness CHRONIC KIDNEY

CHRONIC KIDNEY DISEASE (CKD) Anemia Cardiovascular disease 2 a a 3 t times

chronic kidney disease amp
Chronic Kidney Disease & Mineral

Mechanisms in chronic kidney disease Chronic Kidney Disease & Mineral

3 8 18
3/8/18 Disclosures u I have no

3/8/18 Disclosures u I have no disclosures to report. Chronic Kidney Disease

chronic kidney disease
Chronic Kidney Disease Definition of

Chronic Kidney Disease Definition of CKD Staging of CKD

cardiovascular disease
Cardiovascular disease: Heart disease,

Cardiovascular disease: Heart disease, stroke, chronic kidney disease and

clinical overview chronic kidney disease and diabetic
Clinical Overview : Chronic Kidney

Clinical Overview : Chronic Kidney disease and Diabetic Kidney disease Philip

chronic disease management
chronic disease management: The

PD BUDDy: Mobile technology can provide support in home-based peritoneal

disclosures
Disclosures CHRONIC KIDNEY DISEASE

8/9/2019 Disclosures CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST

yorkshire and humber quality improvement
Yorkshire and Humber Quality

Kidney Quality Improvement Partnership (KQuIP) #KQuIPYH Yorkshire and Humber

keynote address chronic kidney disease global and sri
Keynote Address Chronic Kidney Disease;

Keynote Address Chronic Kidney Disease; Global and Sri Lankan Perspectives Dr

dine amp learn roundtable ckd what to expect
Dine & Learn Roundtable CKD What

Dine & Learn Roundtable CKD What to Expect Dr. Caroline Stigant April 30,

management of management of hypertension hypertension
Management of Management of

Management of Management of Hypertension Hypertension M Misra MD MRCP (UK)

glycocalyx loss
Glycocalyx Loss Podocyte and Kidney

Glycocalyx Loss Podocyte and Kidney Injury Induces Albuminuria Nat Rev

submit
SUBMIT Cas ase P e Presen entat

SUBMIT Cas ase P e Presen entat ation COVID-19 Kurt DeVine, MD and

make it count
Make it count Technical considerations

Make it count Technical considerations and initial findings for accurate

systemic lupus erythematosus presentjng as acute adrenal
Systemic Lupus Erythematosus Presentjng

[Downloaded free from http://www.amhsr.org] Case Report Systemic Lupus

decrements in gfr largely correlates to the
decrements in GFR largely correlates

is a physiological property determine function of all single nephrons taken

optimizing renal function pre and post resection of
Optimizing Renal Function Pre- and

Optimizing Renal Function Pre- and Post-Resection of Kidney Cancer : Important

glomerulonephritis notes
Glomerulonephritis notes ! Neil Turner

24/10/2013' Glomerulonephritis 1 Neil Turner Glomerulonephritis

use of lipoprotein a in clinical practice a biomarker
Use of Lipoprotein(a) in Clinical

Use of Lipoprotein(a) in Clinical Practice: A Biomarker Whose Time Has Come.

hypertension secondary to neonatal hyperleptinaemia
hypertension secondary to neonatal

Note: for non-commercial purposes only KCL Division of Womens Health

4 18 19
4/18/19 SGLT inhibition and Diabetic

4/18/19 SGLT inhibition and Diabetic Kidney Disease Radica Alicic, MD, FHM,